全文获取类型
收费全文 | 1161篇 |
免费 | 64篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 50篇 |
儿科学 | 68篇 |
妇产科学 | 24篇 |
基础医学 | 132篇 |
口腔科学 | 18篇 |
临床医学 | 88篇 |
内科学 | 259篇 |
皮肤病学 | 17篇 |
神经病学 | 183篇 |
特种医学 | 17篇 |
外科学 | 103篇 |
综合类 | 2篇 |
预防医学 | 51篇 |
眼科学 | 5篇 |
药学 | 64篇 |
中国医学 | 2篇 |
肿瘤学 | 148篇 |
出版年
2023年 | 6篇 |
2022年 | 15篇 |
2021年 | 24篇 |
2020年 | 15篇 |
2019年 | 18篇 |
2018年 | 15篇 |
2017年 | 24篇 |
2016年 | 15篇 |
2015年 | 19篇 |
2014年 | 28篇 |
2013年 | 55篇 |
2012年 | 82篇 |
2011年 | 80篇 |
2010年 | 34篇 |
2009年 | 40篇 |
2008年 | 83篇 |
2007年 | 76篇 |
2006年 | 85篇 |
2005年 | 68篇 |
2004年 | 75篇 |
2003年 | 66篇 |
2002年 | 72篇 |
2001年 | 19篇 |
2000年 | 21篇 |
1999年 | 19篇 |
1998年 | 10篇 |
1997年 | 11篇 |
1996年 | 12篇 |
1995年 | 9篇 |
1994年 | 8篇 |
1993年 | 7篇 |
1992年 | 9篇 |
1991年 | 14篇 |
1990年 | 11篇 |
1989年 | 13篇 |
1988年 | 13篇 |
1987年 | 7篇 |
1986年 | 3篇 |
1985年 | 5篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1982年 | 4篇 |
1981年 | 2篇 |
1980年 | 8篇 |
1979年 | 9篇 |
1978年 | 7篇 |
1975年 | 3篇 |
1973年 | 2篇 |
1972年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有1231条查询结果,搜索用时 0 毫秒
11.
Localized scleroderma is distinct from the diffuse form of scleroderma and does not show Raynaud's phenomenon and visceral involvement. The imaging features in 23 patients ranging from 2 to 17 years of age (mean 11.1 years) were reviewed. Leg length discrepancy and muscle atrophy were the most common findings (five patients), with two patients also showing modelling deformity of the fibula. One patient with lower extremity involvement showed abnormal bone marrow signals on MR. Disabling joint contracture requiring orthopedic intervention was noted in one patient. In two patients with en coup de sabre facial deformity, CT and MR scans revealed intracranial calcifications and white matter abnormality in the ipsilateral frontal lobes, with one also showing migrational abnormality. In a third patient, CT revealed white matter abnormality in the ipsilateral parietal lobe. In one patient with progressive facial hemiatrophy, CT and MR scans showed the underlying hypoplastic left maxillary antrum and cheek. Imaging studies of areas of clinical concern revealed positive findings in half our patients. 相似文献
12.
Neurological presentations of mitochondrial diseases 总被引:6,自引:0,他引:6
Summary We present here a report on a 5-year experience in clinical investigation, diagnostic management and molecular genetic studies of neuromitochondrial disorders, defined on the basis of morphological, biochemical and genetic findings. Leigh disease is the most frequent clinical presentation in infancy and childhood, but symptoms at onset are poorly informative. In paediatric cases, lactic acidosis and neuroradiological abnormalities are frequent, and can be of help for the diagnostic orientation. In the adult population, muscle weakness, ophthalmoplegia with ragged-red fibres, retinitis pigmentosa, progressive myoclonal ataxia, and early-onset stroke-like episodes, are frequently combined in complex syndromes that are often familial (maternally inherited) and/or associated with well-established mutations in mitochondrial DNA (mtDNA). However, the presence of overlap syndromes and features common to many neuromitochondrial diseases can complicate the clinical evaluation and the diagnostic approach. The pathogenicity of a given mtDNA mutation can frequently be ascertained by correlating the degree of heteroplasmy with the clinical or biochemical phenotypes. Moreover, transmitochondrial cybrids can be used to test the effects of either mitochondrial or nuclear gene abnormalities in a fully controlled, user-friendly and highly informative system. 相似文献
13.
Franco M. Muggia Kenneth K. Chan Christy Russell Nicoletta Colombo James L. Speyer Kishore Sehgal Susan Jeffers Joan Sorich Lawrence Leichman Uziel Beller E. Mark Beckman 《Cancer chemotherapy and pharmacology》1991,28(4):241-250
Summary Intraperitoneal (i.p.) 5-fluoro-2-deoxyuridine (Floxuridine, FUdR, FdUrd) was evaluated in a phase I study at a starting level of 500 mg given on 1 day in 2 I 1.5% dialysate. Escalations within patients were allowed every other cycle. A total of 23 patients (age, 32–78 years) received 108 treatment courses. Local tolerance at all dose levels was excellent, with no cases of drug-related peritonitis being observed. Nausea and vomiting increased in severity in relation to dose and was universal at >3,000 mg ×3 days. One patient each developed grade 1 mucositis as well as diarrhea at a dose of 3,000 mg×3 days and leukopenia and thrombocytopenia at 5,000 mg×3 days. Peritoneal fluid (PF) and plasma (PL) FdUrd profiles were monitored by an HPLC method in 13 subjects, with 7 being studied serially at 2–4 increment doses for up to 6 h. Profiles that exhibited apparent linear pharmacokinetics gave PF drug levels 2–4 logs higher than the PL counterparts, with the latter essentially declining in parallel to the former, indicating that the disposition of FdUrd from the peritoneal compartment is rate-determining. The mean terminal half-life for PF FdUrd was found to be 115 min and mean peritoneal clearance was 25 ml/min. The vast differences in drug levels and AUC found between the PF and the PL profiles suggests a high systemic clearance of FdUrd, which was confirmed in two patients receiving 2 g FdUrd by short i.v. infusion. A disproportionate increase in the plasma FdUrd levels and the corresponding AUC values was found with increasing dose, suggesting a disproportionate increase in the systemic partitioning of FdUrd when doses were escalated within a patient. Substantial levels of peritoneal 5-fluorouracil (FUra) were also detected in most of the subjects. Thus, FdUrd was found to have several desirable properties for i.p. administration: (1) a 2- to 4-log pharmacologic advantage, (2) the absence of local toxicities, and (3) a favorable antitumor spectrum and some evidence of antitumor effects in this phase I and pharmacology study. A 3,000-mg dose given in 2 l 1.5% dialysate for 3 consecutive days exhibited antitumor activity and produced no systemic toxicity except nausea and vomiting, which was controlled by antiemetics. This dose schedule is therefore recommended for phase II trials directed against small-volume disease in the peritoneal cavity, such as may be found in some stages of ovarian and gastrointestinal cancers. In addition, it is suitable for further exploration as a part of regimens including systemic therapy or drugs that modulate the action of fluoropyrimidines.Supported in part by Cancer Center Core Grant CA 14089, by ROI CA 50 412, by an ACS Institutional Grant (IN21Z, to C. R.) and by the Italian-American Foundation award (to N. C.)Deceased 相似文献
14.
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems 总被引:7,自引:0,他引:7
Simona Romanelli Paola Perego Graziella Pratesi Nives Carenini Monica Tortoreto Franco Zunino 《Cancer chemotherapy and pharmacology》1998,41(5):385-390
Topotecan, a camptothecin analogue, is a␣specific inhibitor of topoisomerase I approved for use in the treatment of patients
with refractory ovarian carcinoma. The drug's mechanism of action suggests a potential efficacy of drug combinations incorporating
DNA-damaging agents. In an attempt better to define a␣rational basis for drug combination we examined the effect of topotecan
on the cytotoxicity and antitumor activity of cisplatin in an ovarian carcinoma system growing in vitro and in vivo as a tumor
xenograft. The in vitro cell system included a cisplatin-sensitive cell line, IGROV-1, and a cisplatin-resistant subline,
IGROV-1/Pt0.5, which is characterized by p53 mutation and loss of normal function of the wild-type gene of the parental cell
line. This cell system was chosen since the cell sensitivity to DNA-damaging agents appears to be dependent on p53 gene status.
Cytotoxicity was assessed by the growth inhibition assay using different schedules: (a) a 1-h period of cisplatin exposure
followed by a 24-h topotecan treatment and (b) a 1-h period of simultaneous exposure to cisplatin and topotecan. In the case
of the sequential schedule, an additive interaction was observed in IGROV-1 and IGROV-1/Pt0.5 cells. When the simultaneous
schedule was used, a synergistic interaction, more evident for the cisplatin-sensitive cells, was found. On the basis of these
observations at a cellular level, the effect of concomitant administration of the two drugs (i.e., the most favorable schedule)
was studied in the IGROV-1 tumor xenograft, which is moderately responsive to cisplatin and topotecan. Suboptimal doses of
each drug (with a low dose of topotecan, 5.1 mg/kg) achieved an antitumor effect comparable with or superior to that of the
optimal dose of a single treatment (tumor weight inhibition, 60%), thus indicating a␣pharmacological advantage of the combination
over the single treatment. However, an increase in the topotecan dose (7.1 mg/kg) was associated with an evident increase
in the toxicity of the combination, thereby suggesting that the drug interaction was not tumor-specific. Although the molecular
basis of the drug interaction is not clear, it is likely that inhibition of topoisomerase I affects the ability of cells to
repair cisplatin adducts. Such findings may have pharmacological implications since they suggest the potential clinical interest
of topoisomerase I inhibitors in combination with cisplatin.
Received: 14 June 1997 / Accepted: 18 September 1997 相似文献
15.
16.
17.
Vanessa Salles Albuquerque Simone Dal Corso Daniel Pereira do Amaral Túlio Medina Dutra de Oliveira Gerson Fonseca Souza Rachel Naara Silva de Souza Ana Karolyn Menezes Nogueira Pedro Dal Lago Maria Luísa Rocha Dadalt Isadora Faraco Correa Graziella Frana Bernardelli Cipriano Fabíola Maria Ferreira Silva Raquel Rodrigues Britto Anderson Jos Carla Malaguti 《Jornal brasileiro de pneumologia》2022,48(4)
18.
ObjectiveBeing a member of the dental profession is often associated with stress and high levels of burnout. Stress coping strategies may significantly help mediate burnout. The present cross-sectional study sought to examine the role of stress coping strategies on burnout, secondary traumatic stress, and compassion satisfaction amongst Israeli dentists.MethodsThe study was carried out amongst Israeli dentists with the use of the following questionnaires: (1) the Professional Quality of Life Scale 5 (ProQOL), referring to burnout, compassion satisfaction, and level of secondary traumatic stress; (2) the Coping Inventory for Stressful Situations–Situation Specific Coping Inventory (CISS-SSC), referring to coping strategies (task-focused, emotion-focused, or avoidance-focused coping); and (3) demographic and professional variables (eg, specialisation, workload). Participants included 243 Israeli dentists. Univariate analyses and linear regressions were conducted to evaluate the relationships amongst coping strategies and burnout, secondary traumatic stress, and compassion satisfaction.ResultsFemale dentists had higher emotion-focused and avoidance coping scores than male dentists. Burnout could be explained by higher emotion-focused coping scores and lower task-focused and avoidance-focused coping. Secondary traumatic stress could be explained by higher emotion-focused scores, having fewer years of professional experience, and younger ages. Compassion satisfaction could be explained by lower emotion-focused coping as well as by higher task-focused coping and workload scores, specialisation, and gender.ConclusionsThe findings suggest that emotional coping may cause dentists to be vulnerable to burnout and to secondary traumatic stress.Key words: Dentistry, Coping strategies, Burnout, Secondary traumatic stress, Professional quality of life, Compassion satisfaction 相似文献
19.
The dose-dependent effects of amikacin on the rat cochlea were studied electrophysiologically using CAP audiograms, amplitude and latency-intensity curves, and CAP tuning curves using a forward masking procedure. The animals were given a daily subcutaneous injection of amikacin in doses ranging from 100 to 1000 mg/kg, for five consecutive days, and were tested one month after the end of the treatment. No functional evidence of ototoxicity was found in animals treated with 100 and 200 mg/kg per day doses of amikacin. The first electrophysiological changes were observed with doses of 300-600 mg/kg per day. They consisted of a broadening of the tip and a hypersensitivity of the tail of the CAP tuning curves, without a change in the CAP threshold sensitivity and latency. Animals treated with 700 mg of amikacin showed an elevation of the tip of the CAP tuning curves and an increase in CAP latency. The classical feature of antibiotic ototoxicity was observed in animals given 800 mg/kg per day of amikacin with an increase in CAP threshold sensitivity and latency, a disruption of the CAP amplitude-intensity function, and a clear hyposensitivity of the CAP tuning curves. These results are discussed in the light of anatomical findings described in a companion paper. 相似文献